Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palovarotene rollover study in participants with fibrodysplasia ossificans progressiva
2021-002244-70Phase 3Completed
- Sponsor
- Ipsen
- Start
- Oct 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of palovarotene in fibrodysplasia ossificans progressiva (FOP), sponsored by Ipsen. Primary endpoint: Incidence and description of treatment-emergent adverse events. Started Oct 2021; status: completed.
02
Drugs
palovarotene
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on 2021-002244-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002244-70.